Author

Lin Wu

Institution: Hunan Cancer Hospital

Observed institution: Hunan Cancer Hospital

ORCID: 0000-0001-7078-7767

Observed ORCID: 0000-0001-7078-7767

OpenAlex ID: A5133857178

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

2026 · Shun Lu, Baogang Liu, et al. · The Lancet · 24

Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

2026 · Yi-Long Wu, Maximilian Hochmair, et al. · New England Journal of Medicine · 22

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.

2026 · Chen Zhiwei, Fang Yang, et al. · Journal of Clinical Oncology · 5

Abstract CT015: Clinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77T

2026 · Tina Cascone, Mark M. Awad, et al. · Cancer Research · 4

SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial

2026 · Runbo Zhong, Huangming Hong, et al. · The Lancet Oncology · 3

Abstract CT014: Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis

2026 · Yi-Long Wu, Wen-Zhao Zhong, et al. · Cancer Research · 3

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 -mutant (HER2m) non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (mets): Results from DESTINY-Lung05 (DL-05).

2026 · Dairong Li, Yong Fang, et al. · Journal of Clinical Oncology · 1

Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study

2026 · Zhanhong Xie, Qiming Wang, et al. · Cancer Research · 1

International Consensus on Severe Lung Cancer—The Second Edition

2026 · Xinqing Lin, Qian Chu, et al. · Translational Lung Cancer Research · 1

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

2026 · Fei Zhou, Chunxia Su, et al. · Nature Communications

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human Study

2026 · Shun Lu, Xinghao Ai, et al. · Research Square

Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial

2026 · Ying Liu, Dairong Li, et al. · Clinical Lung Cancer

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study

2026 · Zhiwei Chen, Fang Yang, et al. · Future Oncology

Pembrolizumab Plus Chemotherapy for Metastatic Squamous Non‒Small-Cell Lung Cancer: Long-Term Follow-Up of the KEYNOTE-407 China Study

2026 · Jie Hu, Ying Cheng, et al. · JTO Clinical and Research Reports

Abstract CT212: Neratinib efficacy in second line patients with EGFR exon 18-mutant non-small-cell lung cancer

2026 · Steve Shen, Wenfeng Fang, et al. · Cancer Research

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human Study

2026 · Shun Lu, Xinghao Ai, et al. · Research Square

The Landscape of Biomarkers in Antibody-Drug Conjugate (ADC)-Treated Non-Small Cell Lung Cancer (NSCLC): A Scoping Review Protocol

2026 · Jingyi Wang, Yu Zhou, et al.

Works count: 17

Citation count: 64

H-index: 4

I10-index: 2